Welcome to our dedicated page for MAXCYTE SEC filings (Ticker: MXCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MaxCyte, Inc. filings document the regulatory record for a Delaware life sciences tools company with Nasdaq-listed common stock. Its Form 8-K disclosures cover operating results and financial condition, corporate presentations, executive appointments, compensatory arrangements, listing-compliance notices, and cost-structure actions tied to workforce and operating changes.
MaxCyte proxy materials cover annual stockholder meeting matters, including director elections, board-class structure and auditor ratification. Together, the filings describe governance, capital-market status, material events, and formal disclosures related to MaxCyte’s cell-engineering platform business, Strategic Platform License model, and public-company reporting obligations.
MaxCyte, Inc. (MXCT) Form 4 – Insider equity grant
On 06/18/2025 non-employee director Rekha Hemrajani received her annual board compensation grant: (i) 29,210 restricted stock units (RSUs) and (ii) a stock option for 50,790 shares with a $2.11 exercise price, expiring 06/17/2035. The RSUs and options were issued under the company’s established Equity Grant Policy for outside directors.
The RSUs convert 1-for-1 into common shares and will vest in full on 06/18/2026, subject to continuous service. No cash was paid for the RSUs (code “A”; price $0). Following the grant, Hemrajani’s direct beneficial ownership increased to 50,577 common shares. No shares were sold or disposed of.
Because the grant is routine, the filing does not necessarily reflect incremental insider sentiment. Nonetheless, it maintains alignment between the director and shareholders and sets a strike price reference at $2.11; upside exists if MXCT trades above that level before 2035.
MaxCyte, Inc. (MXCT) – Form 4 insider filing
Non-employee director Stanley C. Erck reported two compensation-related equity grants dated 18 Jun 2025:
- 29,210 Restricted Stock Units (RSUs) acquired at $0 cost. Each RSU converts to one common share and is scheduled to vest on 18 Jun 2026, conditional on Mr. Erck’s continued board service.
- Stock option for 50,790 shares with an exercise price of $2.11 per share and an expiration date of 17 Jun 2035. The filing classifies the grant as an acquisition (“A”).
Post-transaction, Mr. Erck reports 298,328 common shares held directly. Option holdings now total 50,790 derivative securities.
The filing notes that the equity awards were made under the company’s Equity Grant Policy for non-employee directors. No open-market purchases or sales were disclosed, and there is no indication of a Rule 10b5-1 trading plan for this transaction.
Investor takeaway: The activity reflects routine annual board compensation, modestly increasing insider ownership without immediate cash outlay. It does not signal a change in fundamental outlook or corporate strategy.
MaxCyte, Inc. (ticker: MXCT) filed a Form 4 disclosing routine equity awards to non-employee director Richard Douglas on 18 June 2025. The filing reports two separate grants:
- Restricted Stock Units (RSUs): 29,210 shares of common stock at no cost. These RSUs will vest on 18 June 2026, contingent on Dr. Douglas remaining in continuous service.
- Stock Options: 50,790 options with an exercise price of $2.11 per share, expiring 17 June 2035. The option grant follows the company’s annual equity policy for outside directors.
Following the transaction, Dr. Douglas directly owns 150,577 shares of common stock and holds 50,790 options. The filing indicates the transaction was an automatic annual grant under MaxCyte’s non-employee director compensation plan, not an open-market purchase or sale. No shares were sold or disposed of, and no cash consideration was involved.
Because this is a scheduled board-compensation event rather than a discretionary trade, it generally signals neutral corporate governance housekeeping rather than a directional view on the stock. No other insider transactions, earnings data, or material corporate developments were reported in this filing.
MaxCyte, Inc. (MXCT) – Form 4 insider filing dated 06/23/2025
Independent director Cynthia Collins reported an annual equity grant under the company’s non-employee director compensation program. The grant consists of:
- 29,210 restricted stock units (RSUs) awarded on 06/18/2025 at no cost; each RSU converts into one common share upon vesting on 06/18/2026, assuming continuous board service.
- 50,790 stock options with an exercise price of $2.11 per share, expiring 06/17/2035. Vesting details beyond the standard one-year cliff for RSUs were not disclosed in the filing.
Following the grant, Collins’ direct beneficial ownership increased to 80,889 common shares, strengthening alignment between the director and shareholders. Because the RSUs and options were granted by the company rather than purchased on the open market, the transaction incurs no immediate cash outlay by the insider and does not provide new pricing insight to investors.
No sales, dispositions, or other derivative transactions were reported, and the filing does not contain financial performance data or forward-looking statements. Overall, this is a routine governance disclosure reflecting the company’s ongoing equity-based compensation practice for directors.
MaxCyte, Inc. (MXCT) – Form 4 filing, 23 Jun 2025
Non-employee director William W. Brooke reported routine equity awards dated 18 Jun 2025 under the company’s director Equity Grant Policy:
- 29,210 Restricted Stock Units (RSUs) at no purchase price. Each RSU converts into one common share and vests 18 Jun 2026, contingent on continued board service.
- 50,790 stock options with an exercise price of $2.11 per share, expiring 17 Jun 2035.
Following the transactions, Brooke’s direct beneficial ownership stands at 100,879 common shares plus 50,790 options. No shares were sold or transferred, and the filing does not indicate use of a Rule 10b5-1 trading plan.
The disclosure is administrative in nature, reflecting the annual director grant rather than market purchases or sales.
MaxCyte, Inc. (MXCT) – Form 4 insider transaction
On 06/18/2025, non-employee director Patrick J. Balthrop received his annual equity award under the company’s non-employee director policy. The grant comprises 29,210 restricted stock units (RSUs) and 50,790 stock options with a $2.11 exercise price. RSUs convert 1-for-1 into common shares and vest in full on 06/18/2026, contingent on continued board service. The options expire on 06/17/2035. Following the grant, Balthrop directly owns 50,577 common shares and the newly issued 50,790 options. No open-market purchases or sales occurred, and the transaction price for both RSUs and options was recorded as $0, reflecting a compensatory, not cash, transaction.
The filing is routine and does not signal a change in corporate strategy or financial outlook, but it modestly increases insider equity alignment while introducing potential future dilution should the options be exercised.
MaxCyte, Inc. (MXCT) filed a Form 4 detailing the annual equity grant to non-employee director Dr. Yasir B. Al-Wakeel. On 18 June 2025 he received 29,210 restricted stock units (RSUs), each representing one share of common stock, at a cost basis of $0. The RSUs will vest in full on 18 June 2026, provided he remains in service on that date. Following the award, Dr. Al-Wakeel’s direct beneficial ownership of common stock stands at 50,577 shares.
In addition, he was granted a stock option covering 50,790 shares of common stock at an exercise price of $2.11 per share. The option was issued on 18 June 2025 and expires on 17 June 2035. All derivative securities are held directly.
The filing is purely an insider ownership update; it discloses no sales, no cash transactions, and no changes to company fundamentals. The equity awards were made under the company’s standard policy for non-employee directors and are accompanied by a power of attorney (Exhibit 24) authorising an attorney-in-fact to sign on the director’s behalf.